SBIO
ALPS Medical Breakthroughs ETF
S-Network Medical Breakthroughs TR USD
NAV as of
4 Week: 27.35 - 30.58
52 Week: 23.99 - 36.16
Latest Closing Price
27.48
Premium / Discount
0.05
Expense Ratio
0.5%
Investment Objective
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -9.55 | 1.73 | -5.52 |
| 1 Day | -1.16 | 0.00 | 0.00 |
| 1 Week | -3.63 | 2.19 | -1.66 |
| 1 Month | -10.13 | 8.27 | -1.22 |
| 3 Months | -7.57 | 14.03 | -0.54 |
| 6 Months | -8.89 | 23.31 | -0.38 |
| 1 Year | -17.26 | 41.61 | -0.41 |
| 2 Years | -48.63 | 53.83 | -0.90 |
| 3 Years | -4.95 | 65.08 | -0.08 |
| 5 Years | -23.56 | 81.56 | -0.29 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 28.0775 | -27.6539 | 44.9849 | -11.1926 | 49.8643 | 21.2092 | -17.5497 | -27.8577 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 1.0000 | 99.0000 | 4.0000 | 88.0000 | 3.0000 | 54.0000 | 93.0000 | 82.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| N.A | ||
Portfolio Data
Total Number of Holdings: 119
Number of Bond Holdings: 0
Number of Equity Holdings: 116
Total Market Value: 98,766,790
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | ACADIA Pharmaceuticals Inc | 4.9580 | 205,370 | 0 | 8,717,956 |
| 2 | United Therapeutics Corp | 4.3584 | 85,020 | 0 | 7,663,703 |
| 3 | Mirati Therapeutics Inc | 4.2158 | 76,225 | 0 | 7,412,881 |
| 4 | MorphoSys AG ADR | 3.9422 | 246,857 | 0 | 6,931,745 |
| 5 | Allakos Inc | 3.7367 | 93,863 | 0 | 6,570,410 |
| 6 | Immunomedics Inc | 3.6525 | 372,309 | 0 | 6,422,330 |
| 7 | FibroGen Inc | 3.5492 | 168,624 | 0 | 6,240,774 |
| 8 | Alkermes PLC | 3.5017 | 304,964 | 0 | 6,157,223 |
| 9 | Global Blood Therapeutics Inc | 3.2780 | 116,420 | 0 | 5,763,954 |
| 10 | Emergent BioSolutions Inc | 3.2125 | 99,873 | 0 | 5,648,817 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 0.00 |
| Large | 0.00 |
| Medium | 9.65 |
| Small | 52.39 |
| Micro | 37.98 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
8.6692
Price/Book*
2.7938
Price/Sales*
1.9110
Price/Cash Flow*
4.4301
Dividend Yield*
0.0000
Growth Measures
Long-Term Earnings
0.0000
Historical Earnings
13.3783
Sales Growth
18.8651
Cash-Flow Growth
-6.0304
Book-Value Growth
-2.2359
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
